Mixed results so far for biosimilars in B.C.; Alberta announces own program
The first phase of B.C.’s precedent-setting Biosimilars Initiative appears to have gone smoothly, yet claims data indicate that less than half of affected patients actually made the switch. Meanwhile, Alberta launches its own biosimilar switching program.
